Get started
Author

Maximilian J. Mair

Observed names: J. Mair Maximilian, M J Mair, M M Mair, M Mair, M. Mair, M.J. Mair, Mair, Maximilian J, Mair, Maximilian J., Maximilian J Mair, Maximilian Johannes Mair, Maximilian Mair
Observed institutions: University of Vienna, Vienna General Hospital, LMU Klinikum, Comprehensive Cancer Center Vienna, Klinik und Poliklinik für Nuklearmedizin, München Klinik, Medical University of Vienna, Ludwig-Maximilians-Universität München
ORCID: 0000-0002-6537-3874
Observed ORCID: 0000-0002-6537-3874
OpenAlex ID: A5086579607
PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group
2024 · Nathalie L Albert, Norbert Galldiks, et al. · The Lancet Oncology · 158
Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours
2023 · Maximilian J. Mair, Rupert Bartsch, et al. · Nature Reviews Clinical Oncology · 100
A basic review on systemic treatment options in WHO grade II-III gliomas
2020 · Maximilian J. Mair, Marjolein Geurts, et al. · Cancer Treatment Reviews · 94
PDF
Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG)
2021 · Matthias Preusser, Antonio Silvani, et al. · Neuro-Oncology · 81
PDF
Emerging systemic treatment options in meningioma
2022 · Maximilian J. Mair, Anna S. Berghoff, et al. · Journal of Neuro-Oncology · 79
PDF
Neurological complications of cancer immunotherapy
2021 · Patrick Roth, Sebastian Winklhofer, et al. · Cancer Treatment Reviews · 77
PDF
Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases
2024 · Rupert Bartsch, Anna Sophie Berghoff, et al. · Neuro-Oncology · 68
PDF
Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations
2021 · Maximilian J. Mair, Julia M. Berger, et al. · JAMA Oncology · 65
PDF
Update to the RANO working group and EANO recommendations for the clinical use of PET imaging in gliomas
2025 · Norbert Galldiks, Philipp Lohmann, et al. · The Lancet Oncology · 49
LAG-3 expression in the inflammatory microenvironment of glioma
2021 · Maximilian J. Mair, Barbara Kiesel, et al. · Journal of Neuro-Oncology · 43
PDF
Clinical characteristics and prognostic factors of adult patients with pilocytic astrocytoma
2020 · Maximilian J. Mair, Adelheid Wöhrer, et al. · Journal of Neuro-Oncology · 42
PDF
Systemic inflammation scores correlate with survival prognosis in patients with newly diagnosed brain metastases
2021 · Angelika M. Starzer, Ariane Steindl, et al. · British Journal of Cancer · 39
PDF
European Association of Neuro-Oncology guideline on molecular testing of meningiomas for targeted therapy selection
2024 · Felix Sahm, Luca Bertero, et al. · Neuro-Oncology · 38
Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron
2022 · Maximilian J. Mair, Manfred Mitterer, et al. · Cancer Cell · 36
PDF
Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events – a retrospective cohort study
2022 · Maximilian J. Mair, Julia M. Berger, et al. · European Journal of Cancer · 35
PDF
RANO criteria for response assessment of brain metastases based on amino acid PET imaging
2025 · Nathalie L. Albert, Norbert Galldiks, et al. · Nature Medicine · 33
PDF
Translating the theranostic concept to neuro-oncology: disrupting barriers
2024 · Nathalie L Albert, Emilie Le Rhun, et al. · The Lancet Oncology · 31
Independent prognostic impact of DNA methylation class and chromosome 1p loss in WHO grade 2 and 3 meningioma undergoing adjuvant high-dose radiotherapy: comprehensive molecular analysis of EORTC 22042–26042
2023 · Sybren L. N. Maas, Philipp Sievers, et al. · Acta Neuropathologica · 29
Immunotherapy for brain metastases and primary brain tumors
2022 · Anna M. Di Giacomo, Maximilian J. Mair, et al. · European Journal of Cancer · 28
PDF
Radioligand therapies in meningioma: Evidence and future directions
2024 · Maximilian J Mair, Emeline Tabouret, et al. · Neuro-Oncology · 27
PDF
Prognostic factors in adult brainstem glioma: a tertiary care center analysis and review of the literature
2021 · Annette Leibetseder, Johannes Leitner, et al. · Journal of Neurology · 27
PDF
Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours
2020 · Maximilian J. Mair, Sahra Pajenda, et al. · ESMO Open · 26
Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases
2021 · A. Steindl, D. Alpar, et al. · ESMO Open · 21
PDF
Early Postoperative Treatment versus Initial Observation in CNS WHO Grade 2 and 3 Oligodendroglioma: Clinical Outcomes and DNA Methylation Patterns
2022 · Maximilian J. Mair, Annette Leibetseder, et al. · Clinical Cancer Research · 20
PDF
Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance
2017 · B Englinger, M Mair, et al. · British Journal of Cancer · 16
PDF
Works count: 144
Citation count: 1,404
H-index: 22
I10-index: 28
Year
Topic
Type